Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-?2a treatment

Basit Öğe Kaydı
dc.contributor.authorMederacke, Ingmar
dc.contributor.authorYurdaydin, Cihan
dc.contributor.authorDalekos, George N.
dc.contributor.authorBremer, Birgit
dc.contributor.authorErhardt, Andreas
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorYalcin, Kendal
dc.date.accessioned2024-04-24T17:20:58Z
dc.date.available2024-04-24T17:20:58Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone. Methods: Sera from 33 HDV-RNA-positive patients from the international HIDIT-1 trial were available for anti-HDV IgM testing (ETI-DELTA-IGMK-2 assay, DiaSorin, Saluggia, Italy) before therapy, at treatment weeks 24 and 48, and at 24 weeks after the end of treatment. Results: Anti-HDV IgM tested positive in 31 out of the 33 patients (94%) prior to treatment. HDV IgM levels correlated with histological inflammatory activity (r= 0.51, P<0.01) and were higher in patients with alanine aminotransferase and gamma-glutamyl transpeptidase levels above the median (P<0.05). Quantitative anti-HDV IgM values declined in patients responding to antiviral therapy, however anti-HDV IgM remained positive after treatment in the majority of virological responders. Conclusions: We suggest that anti-HDV IgM testing might give additional useful information to determine disease activity in hepatitis delta and to predict treatment response to antiviral therapy with type I interferons. However, determination of anti-HDV IgM can not substitute HDV RNA testing, which remains the primary virological marker for response to therapy.en_US
dc.description.sponsorshipHep-Net Study House; German Ministry for Education and Research; BMBF; Hoffmann-La Roche; Gilead Sciences; F Hoffmann-La Rocheen_US
dc.description.sponsorshipThis study was funded by the Hep-Net Study House (a national network sponsored by the German Ministry for Education and Research; BMBF), Hoffmann-La Roche and Gilead Sciences. HW, CY, GND, AE, SZ and MPM have received research grants, lecturer fees, and travel support from F Hoffmann-La Roche and Gilead Sciences. IM has received research grants from F Hoffmann-La Roche and travel support from Gilead Sciences. All other authors declare no competing interests.en_US
dc.identifier.doi10.3851/IMP1926
dc.identifier.endpage312en_US
dc.identifier.issn1359-6535
dc.identifier.issue2en_US
dc.identifier.pmid22293066
dc.identifier.scopus2-s2.0-84860326665
dc.identifier.scopusqualityQ3
dc.identifier.startpage305en_US
dc.identifier.urihttps://doi.org/10.3851/IMP1926
dc.identifier.urihttps://hdl.handle.net/11468/19320
dc.identifier.volume17en_US
dc.identifier.wosWOS:000303987200006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherInt Medical Press Ltden_US
dc.relation.ispartofAntiviral Therapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleAnti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-?2a treatmenten_US
dc.titleAnti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-?2a treatment
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu